New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:41 EDTANIPANI Pharmaceuticals fundamentals appear on track, says Roth Capital
After ANI's stock came under considerable pressure, Roth Capital spoke with the company's management and thinks the company's fundamentals remain on track. The firm believes that the company's revenue and EPS could beat expectations, and it reiterates a Buy rating on the stock.
News For ANIP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
08:08 EDTANIPANI Pharmaceuticals and Sofgen announce FDA approval of nimodipine capsules
ANI Pharmaceuticals announced that its ANDA collaboration partner Sofgen has received approval from the FDA of the Abbreviated New Drug Application for Nimodipine 30mg Capsules. Trailing twelve-month sales for the product are $25 million, according to IMS Health, with two current competitors. ANI and Sofgen expect to begin shipping to customers this year.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use